Close Menu

NEW YORK – Qiagen late on Monday received Emergency Use Authorization from the US Food and Drug Administration for the QiaStat-Dx Respiratory SARS-CoV-2 Panel for use in diagnosing patients infected with the coronavirus causing COVID-19.

The panel can detect and differentiate SARS-CoV-2 and 20 other viral and bacterial pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients, and will become the first "syndromic" testing product to be deployed in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.